Behavioral Health

Brief psychotic disorder and schizophreniform

Clinical Overview and When to Suspect Brief Psychotic Disorder and Schizophreniform

— Brief psychotic disorder: ≥1 positive symptom (delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior) lasting ≥1 day but <1 month, with eventual full return to premorbid functioning.

— Schizophreniform disorder: same symptom criteria as schizophrenia (≥2 symptoms, with at least one being delusions, hallucinations, or disorganized speech) lasting ≥1 month but <6 months.

— Schizophrenia: identical symptom set persisting ≥6 months (including prodromal/residual).

— Young adult (late teens–30s) with first-episode psychosis and no chronic psychiatric history.

— Acute onset of bizarre behavior, paranoia, or hallucinations within days to weeks of a major stressor (immigration, postpartum, bereavement, combat) → think BPD.

— Subacute psychosis present >1 month but not yet 6 months, often referred from ED or primary care → think schizophreniform.

— BPD: with marked stressor(s), without marked stressor(s), with postpartum onset (within 4 weeks of delivery).

— Schizophreniform: with good prognostic features (acute onset within 4 weeks, confusion at peak, good premorbid function, absence of blunted affect) or without.

Board pearl: Duration is the discriminator. <1 month = brief; 1–6 months = schizophreniform; ≥6 months = schizophrenia. The DSM-5 stopwatch matters more than symptom severity for the diagnostic label, and roughly two-thirds of schizophreniform patients eventually progress to schizophrenia or schizoaffective disorder.

Brief psychotic disorder (BPD) and schizophreniform disorder are time-defined psychotic syndromes on the schizophrenia spectrum, distinguished from schizophrenia primarily by duration.

When to suspect on Step 3:

Specifiers:

Provisional diagnosis applies when duration criteria cannot yet be met but symptoms otherwise qualify — must be revised as the timeline clarifies.

Presentation Patterns and Key History

— A 24-year-old graduate student, no prior psychiatric history, 1 week after her mother's sudden death develops the conviction that neighbors are broadcasting her thoughts on the radio. She is brought in by family; symptoms resolve over 3 weeks with supportive care and low-dose antipsychotic.

— Postpartum-onset BPD: woman within 4 weeks of delivery develops command auditory hallucinations to harm infant, delusions about the baby being switched/possessed — this is a psychiatric emergency and overlaps with postpartum psychosis.

— A 19-year-old college freshman over 6 weeks becomes withdrawn, stops attending class, accuses roommates of poisoning him, hears two voices commenting on his actions. Symptoms persist 3 months at presentation.

— Exact onset and duration of each symptom (build the DSM timeline).

— Substance use: cannabis, methamphetamine, cocaine, LSD, synthetic cannabinoids, PCP, high-dose corticosteroids, anticholinergics — all can mimic.

— Medical review: fever, headache, seizures, autoimmune disease, recent infection (anti-NMDA receptor encephalitis), thyroid symptoms.

— Family history of schizophrenia, bipolar disorder, suicide.

— Stressors: especially in BPD — bereavement, migration, trauma, postpartum status.

— Premorbid functioning: school/work performance, social relationships — preserved functioning favors BPD or good-prognosis schizophreniform.

— Mood symptoms: rule out major depressive or manic episodes that would shift toward mood disorder with psychotic features or schizoaffective disorder.

— Safety: suicidal ideation, homicidal ideation, command hallucinations, ability to care for self.

Step 3 management: Always collect collateral history from family or roommates — patients with active psychosis frequently lack insight, and the duration timeline (which dictates the diagnosis) often comes from observers, not the patient. Document the exact day symptoms began.

Prototypical brief psychotic disorder vignette:

Prototypical schizophreniform vignette:

Key historical elements to elicit:

Physical Exam Findings and Mental Status Assessment

— Fever + psychosis → encephalitis, neuroleptic malignant syndrome, sepsis, anti-NMDA receptor encephalitis, thyroid storm.

— Tachycardia, hypertension, mydriasis, diaphoresis → sympathomimetic intoxication (cocaine, meth, PCP).

— Miosis, hypoventilation → opioid (psychosis less likely but consider mixed).

— Cranial nerves, focal deficits, gait, tremor, rigidity, abnormal involuntary movements.

— Orofacial dyskinesias, autonomic instability, seizures → think anti-NMDA receptor encephalitis (young women, often with ovarian teratoma).

— Asterixis, myoclonus → metabolic encephalopathy.

— Appearance/behavior: agitation, guardedness, response to internal stimuli.

— Speech: pressured, disorganized, tangential, word salad, neologisms.

— Mood/affect: anxious, labile, incongruent, flat.

— Thought process: loose associations, flight of ideas, thought blocking.

— Thought content: delusions (persecutory, grandiose, referential, somatic, bizarre), suicidal/homicidal ideation, thought insertion/withdrawal/broadcasting.

— Perceptions: auditory > visual hallucinations (visual hallucinations should raise suspicion for delirium, substance, or neurologic cause).

— Cognition: orientation, attention, memory — clouded sensorium suggests delirium, not primary psychosis.

— Insight and judgment: typically poor.

Key distinction: Primary psychotic disorders preserve orientation and level of consciousness. Disorientation, fluctuating arousal, or visual hallucinations should redirect you toward delirium or a medical/toxic cause before settling on BPD or schizophreniform.

General appearance: disheveled grooming, inappropriate clothing, psychomotor agitation or retardation, catatonic posturing in severe cases.

Vital signs — critical to obtain, because abnormal vitals push you toward a medical etiology:

Neurologic exam (must be documented in first-episode psychosis):

Mental status exam (MSE) — the core data:

Diagnostic Workup — Initial Labs, Imaging, and Toxicology

— CBC, CMP (electrolytes, BUN/Cr, glucose, LFTs, calcium).

— TSH — hypo- and hyperthyroidism both produce psychiatric symptoms.

— Vitamin B12, folate — especially in elderly or malnourished.

— HIV and RPR/syphilis serology — neurosyphilis and HIV-associated psychosis remain on the differential.

— Pregnancy test (β-hCG) in any reproductive-age woman before antipsychotics or imaging.

— CRP/ESR if autoimmune suspicion.

— Urine drug screen: cannabis, cocaine, amphetamines, PCP, opioids, benzodiazepines.

— Remember UDS misses synthetic cannabinoids, LSD, MDMA, bath salts, ketamine — order specific assays if suspected.

— Blood alcohol level.

— Baseline QTc before starting antipsychotics, particularly ziprasidone, IV haloperidol, thioridazine.

— Repeat after dose stabilization or any QT-prolonging combination.

— MRI brain (preferred) or non-contrast CT in first-episode psychosis to exclude tumor, demyelination, stroke, hydrocephalus, especially with focal neurologic findings, new-onset psychosis >40, atypical features.

— Weight/BMI, waist circumference, BP, fasting glucose or HbA1c, fasting lipid panel.

— Document before second-generation antipsychotic (SGA) is started.

Step 3 management: In a first-episode psychosis ED encounter, the standard order set is CBC, CMP, TSH, UDS, BAL, β-hCG, RPR, HIV, ECG, and MRI brain — plus weight, BMI, and fasting metabolic panel before SGA initiation. Skipping this workup is a frequently tested error.

First-episode psychosis workup is a Step 3 favorite. You must rule out medical/substance causes before committing to a primary psychiatric diagnosis.

Baseline labs:

Toxicology:

ECG:

Neuroimaging:

Metabolic baseline before antipsychotic initiation (ADA/APA consensus):

Diagnostic Workup — Advanced and Confirmatory Studies

— Fever, seizures, autonomic instability, movement disorder, dyskinesias → autoimmune encephalitis panel.

— Rapidly progressive cognitive decline → CSF analysis, EEG, dementia workup.

— Focal neuro signs or new psychosis after age 40 → MRI with and without contrast.

— Young woman, prodromal viral-like illness, then psychosis, dyskinesias, seizures, autonomic instability, dysautonomia.

— Workup: CSF anti-NMDA receptor antibodies, EEG (extreme delta brush), pelvic imaging for ovarian teratoma.

— Treatment: tumor removal + IV steroids, IVIG, plasmapheresis; rituximab/cyclophosphamide if refractory.

— DSM-5 criteria checklist; longitudinal observation is often the most powerful "test" — repeat MSE daily.

— Use collateral interviews to confirm symptom onset date for duration criteria.

Board pearl: A young woman with new-onset psychosis, orofacial dyskinesias, seizures, and autonomic instability is anti-NMDA receptor encephalitis until proven otherwise — order CSF antibodies and pelvic ultrasound/MRI for a teratoma before locking in a primary psychotic diagnosis.

When to extend the workup beyond the standard first-episode battery:

Anti-NMDA receptor encephalitis (must-know mimic):

EEG indications: suspected seizure-related psychosis, postictal psychosis, nonconvulsive status, delirium with unclear etiology.

Lumbar puncture: fever + altered mental status, immunocompromise, suspected encephalitis, or unexplained psychosis with neurologic signs.

Heavy metal screening (lead, mercury, manganese) only with occupational/environmental exposure.

Wilson disease: ceruloplasmin, 24-hr urinary copper, slit-lamp for Kayser-Fleischer rings in psychosis with movement disorder or hepatic dysfunction in patients <40.

Porphyria (24-hr urinary porphobilinogen) for episodic psychosis + abdominal pain + neuropathy.

Genetic/structured assessment: not part of acute workup; consider 22q11.2 deletion (velocardiofacial syndrome) in young patient with dysmorphic features, cardiac defects, hypocalcemia, and psychosis.

Structured psychiatric assessment:

Risk Stratification and First-Line Management Logic

— Inpatient psychiatric admission indicated when: danger to self/others, command hallucinations, inability to perform self-care, lack of safe outpatient supervision, severe agitation, catatonia, or first-episode psychosis requiring stabilization.

— Outpatient management acceptable if: mild symptoms, intact reality testing in some domains, reliable caregiver, no safety concerns, rapid follow-up.

— Verbal de-escalation first: calm environment, low stimulation, single staff member, offer food/water.

— PO preferred if cooperative: olanzapine 5–10 mg PO/ODT, risperidone 2 mg PO, or oral haloperidol + lorazepam.

— IM if refusing or severely agitated: olanzapine 10 mg IM, haloperidol 5 mg + lorazepam 2 mg IM ("B-52" without diphenhydramine if no EPS risk), or ziprasidone 10–20 mg IM.

— Avoid IM olanzapine + IM benzodiazepine simultaneously → respiratory depression, hypotension.

— Provisional BPD if <1 month with planned reassessment.

— Provisional schizophreniform if ≥1 month but <6 months.

— Substance use → addiction consult, motivational interviewing.

— Psychosocial stressors → social work, supportive psychotherapy.

— Sleep deprivation → sleep hygiene, short-term sedative-hypnotic if needed.

CCS pearl: In a CCS-style first-episode psychosis case, order in sequence: vitals → place in safe quiet room → labs/UDS/ECG/MRI → IM olanzapine or haloperidol+lorazepam if agitated → admit to psychiatry → start scheduled SGA → psychiatry consult → social work → metabolic baseline → discharge planning with 1-week follow-up.

Step 1 — Determine setting:

Step 2 — Acute agitation control (CCS-style):

Step 3 — Establish working diagnosis:

Step 4 — Initiate antipsychotic (see chunk 7).

Step 5 — Address contributors:

Step 6 — Plan follow-up: psychiatry within 1 week of discharge; coordinate with primary care.

Pharmacotherapy — First-Line Antipsychotic Regimen

— Risperidone 1–2 mg/day, titrate to 2–6 mg/day. Watch for hyperprolactinemia, EPS at higher doses.

— Olanzapine 5–10 mg/day, titrate to 10–20 mg/day. Best efficacy in many trials but highest metabolic burden (weight gain, dyslipidemia, diabetes).

— Aripiprazole 10–15 mg/day, titrate to 15–30 mg/day. Partial D2 agonist; weight-neutral, akathisia common.

— Quetiapine less preferred for primary psychosis; better for mood with psychotic features.

— Ziprasidone weight-neutral but QT prolongation, must take with food (≥500 kcal) for absorption.

— Lurasidone, paliperidone, brexpiprazole, cariprazine are reasonable alternatives.

— Brief psychotic disorder: continue antipsychotic for 1–3 months after symptom resolution, then taper with close monitoring.

— Schizophreniform: continue for at least 12 months after remission; many patients will progress and require indefinite therapy.

— Benzodiazepines (lorazepam) for acute agitation, catatonia (lorazepam challenge test).

— Beta-blockers (propranolol) or benztropine for akathisia and EPS.

— Anticholinergics (benztropine, diphenhydramine) for acute dystonia — IM benztropine 1–2 mg.

Step 3 management: Choose aripiprazole in a young patient where metabolic side effects matter most; choose olanzapine when rapid behavioral control trumps long-term metabolic concerns; switch agents at 4–6 weeks if no response at therapeutic dose.

First-line: second-generation antipsychotics (SGAs) for both BPD and schizophreniform — better tolerability and lower EPS risk than first-generation agents.

Duration of treatment:

Avoid clozapine first-line — reserved for treatment-resistant schizophrenia (≥2 failed antipsychotic trials).

First-generation antipsychotics (haloperidol, fluphenazine): still used acutely; long-acting injectables (LAIs) considered if adherence is a concern — paliperidone, aripiprazole, risperidone LAIs.

Adjuncts:

Expanded Pharmacology — Side Effects, Monitoring, and Switching

— Acute dystonia (hours–days): torticollis, oculogyric crisis, laryngospasm. Treat IM benztropine 1–2 mg or IM diphenhydramine 50 mg.

— Akathisia (days–weeks): inner restlessness, pacing. Treat propranolol 10–20 mg TID, lower dose, or switch.

— Parkinsonism (weeks): bradykinesia, rigidity, tremor. Treat with benztropine, amantadine, or dose reduction.

— Tardive dyskinesia (months–years): choreoathetoid orofacial movements. Treat with VMAT2 inhibitors — valbenazine, deutetrabenazine; discontinue offending agent if possible.

— Monitor weight monthly × 3 months then quarterly; fasting glucose/HbA1c and lipids at 3 months then annually.

— Lifestyle counseling, metformin if persistent weight gain.

— Galactorrhea, amenorrhea, sexual dysfunction, gynecomastia. Switch to aripiprazole or add it as adjunct.

— Fever, lead-pipe rigidity, autonomic instability, altered mental status, elevated CK, leukocytosis.

— Treat: stop antipsychotic, supportive care, dantrolene, bromocriptine, ICU.

Board pearl: Acute dystonia in a young Black male hours after starting haloperidol → IM benztropine immediately, then transition to an SGA. Never give "wait and see" advice — laryngospasm can be fatal.

Extrapyramidal symptoms (EPS) — more common with FGAs and high-dose risperidone:

Metabolic syndrome (SGAs, especially olanzapine, clozapine):

Hyperprolactinemia (risperidone, paliperidone, FGAs):

Neuroleptic malignant syndrome (NMS):

QT prolongation: monitor ECG with ziprasidone, IV haloperidol, thioridazine, especially with other QT drugs.

Agranulocytosis: clozapine requires REMS-mandated weekly ANC ×6 months, then biweekly ×6 months, then monthly.

Switching strategy: cross-taper over 2–4 weeks; avoid abrupt discontinuation (cholinergic rebound, withdrawal dyskinesia).

Special Populations — Elderly and Renal/Hepatic Impairment

— Always exclude dementia (Alzheimer, Lewy body, frontotemporal), delirium, stroke, tumor, metabolic derangement, medication-induced psychosis (steroids, anticholinergics, dopamine agonists in Parkinson disease).

— BPD and schizophreniform can still occur but are uncommon late-onset diagnoses.

— FDA black-box warning: antipsychotics increase mortality (~1.6–1.7×) and stroke risk in elderly patients with dementia-related psychosis. Use only when nonpharmacologic measures fail and symptoms cause significant distress or danger.

— Start low, go slow: risperidone 0.25–0.5 mg, olanzapine 2.5 mg, aripiprazole 2–5 mg, quetiapine 12.5–25 mg.

— Avoid anticholinergics (benztropine, diphenhydramine) — delirium risk; per Beers criteria.

— Fall risk from orthostasis, sedation; check orthostatic vitals.

— Paliperidone is renally cleared — reduce dose or avoid in CrCl <50.

— Risperidone, amisulpride require renal dose adjustment.

— Olanzapine, aripiprazole, quetiapine are hepatically metabolized — generally safer in CKD.

— Most antipsychotics undergo hepatic metabolism (CYP2D6, CYP3A4). Reduce doses in cirrhosis; avoid chlorpromazine (cholestasis).

— Monitor LFTs at baseline and periodically with quetiapine, olanzapine.

Step 3 management: In an elderly patient with new psychosis, your first move is workup for delirium and dementia, not initiation of an antipsychotic. If pharmacotherapy is unavoidable, use the lowest dose of a low-anticholinergic SGA and document discussion of black-box mortality risk.

Late-onset psychosis (>40 years) demands a broader differential:

Antipsychotic risks in elderly:

Renal impairment:

Hepatic impairment:

Drug interactions: CYP inducers (carbamazepine, rifampin, smoking — induces CYP1A2 affecting olanzapine/clozapine) and inhibitors (fluoxetine, paroxetine — increase risperidone, aripiprazole levels).

Special Populations — Pregnancy, Postpartum, and Pediatrics

— Onset within 4 weeks of delivery (DSM); peak incidence in first 2 weeks.

— Symptoms: delusions (often about the infant), command hallucinations, severe mood lability, confusion.

— Risk factors: bipolar disorder, prior postpartum psychosis (recurrence ~30–50%), primiparity, sleep deprivation, family history.

— Psychiatric emergency — risk of infanticide (~4%) and suicide (~5%). Admit immediately, separate mother from infant under supervision until safe, ECT or antipsychotic + mood stabilizer.

— Untreated psychosis carries fetal risks (poor prenatal care, malnutrition, substance use). Treat rather than withhold.

— Haloperidol, risperidone, olanzapine, quetiapine have the most reproductive safety data; generally not teratogenic.

— Avoid valproate (neural tube defects) and paroxetine if mood stabilization is needed.

— Third-trimester antipsychotic exposure: monitor neonate for EPS, sedation, withdrawal symptoms.

— Schizophreniform/BPD diagnoses are valid in adolescents; symptom criteria identical.

— Aripiprazole and risperidone are FDA-approved for adolescent schizophrenia.

— Monitor growth, prolactin, metabolic parameters more closely; adolescents have higher weight gain susceptibility to SGAs.

— Address school accommodations (504 plan/IEP), family psychoeducation, substance use screening (cannabis is a major contributor in adolescent first-episode psychosis).

Board pearl: A new mother 10 days postpartum with delusions that her infant is the devil and command hallucinations to drown the baby → immediate hospitalization, do not discharge home, supervised contact only, start antipsychotic ± mood stabilizer, evaluate for ECT if severe. This is one of psychiatry's true emergencies.

Postpartum-onset brief psychotic disorder / postpartum psychosis:

Antipsychotics in pregnancy:

Breastfeeding: olanzapine, quetiapine, risperidone have low milk transfer — generally compatible with breastfeeding under monitoring. Lithium is relatively contraindicated.

Pediatric/adolescent considerations:

Complications and Adverse Outcomes

— Schizophreniform disorder progresses to schizophrenia in roughly two-thirds of cases; another portion evolves into schizoaffective or bipolar with psychotic features.

— Brief psychotic disorder has a better prognosis — many patients have no recurrence, though some develop mood or psychotic disorders later (~30–50% over years).

— First-episode psychosis carries a lifetime suicide risk ~5%, with highest risk in early illness and immediately post-discharge.

— Risk factors: command auditory hallucinations, depressive symptoms, prior attempts, substance use, recent loss, awareness of illness (insight returning).

— Acute psychosis modestly elevates violence risk, primarily when paired with substance use or persecutory delusions targeting specific persons.

— Self-neglect → dehydration, malnutrition, hypothermia, missed medical care.

— Metabolic syndrome, diabetes, weight gain with SGAs.

— Tardive dyskinesia with cumulative antipsychotic exposure.

— NMS (rare but life-threatening).

— Hyperprolactinemia → osteoporosis with chronic use.

— QT prolongation, arrhythmia.

— Sedation, falls, anticholinergic delirium (especially elderly).

Key distinction: A patient whose schizophreniform symptoms persist beyond 6 months is reclassified as schizophrenia — not a treatment failure, but a diagnostic update. Counsel the family at month 4–5 about this likely transition and what indefinite maintenance therapy will entail.

Progression to chronic psychotic illness:

Suicide:

Violence and self-neglect:

Iatrogenic complications:

Substance use comorbidity: high rates of cannabis, alcohol, tobacco use; worsens prognosis.

Social/occupational decline: school dropout, job loss, relationship disruption, housing instability.

Trauma from psychosis: distressing hallucinations or involuntary hospitalization can cause post-psychotic PTSD-like symptoms.

When to Escalate Care — Inpatient Admission and Consultation

— Active suicidal or homicidal ideation with plan/intent.

— Command auditory hallucinations directing harm.

— Inability to care for self (not eating, not drinking, not seeking shelter).

— Severe agitation or catatonia requiring close monitoring.

— Postpartum psychosis — always admit.

— First-episode psychosis when outpatient stabilization is unsafe or unfeasible.

— Failure of outpatient treatment: worsening despite adequate trial.

— Mental illness AND

— Danger to self OR danger to others OR grave disability.

— Document specific behaviors, statements, and clinical findings supporting each criterion.

— Neurology for focal signs, seizures, suspected encephalitis, abnormal MRI.

— Internal medicine for medical workup of new-onset psychosis, especially in older adults.

— OB/Gyn for postpartum or pregnant patients.

— Suspected NMS, serotonin syndrome, severe alcohol/sedative withdrawal.

— Anticholinergic toxidrome with hyperthermia.

— Hemodynamic instability.

— Concurrent medical emergency masquerading as psychosis (DKA, hepatic encephalopathy, hypoxia).

— Early intervention/coordinated specialty care (CSC) programs for first-episode psychosis — RAISE-style team-based care reduces relapse and improves function.

— Substance use treatment if comorbid.

— Case management, supported employment, supported education.

CCS pearl: Order set for involuntary admission: document specific safety concerns, complete state-specific hold paperwork (e.g., 5150 in California, 72-hour hold), notify family if patient permits, arrange psychiatric transport, do not let patient sign out AMA during the hold, reassess capacity daily.

Immediate inpatient psychiatric admission indications:

Involuntary hold criteria (varies by state, but generally requires):

Medical consultation:

ICU/medical admission required when:

Specialty referrals after stabilization:

Key Differentials — Same-Category (Psychotic Spectrum)

— Same symptom criteria as schizophreniform but ≥6 months total (including prodromal/residual). Functional decline is required.

— Psychotic symptoms PLUS major mood episodes (manic or major depressive). Psychotic symptoms must occur for ≥2 weeks in the absence of a mood episode at some point — this is the key separator from mood disorder with psychotic features.

— ≥1 non-bizarre delusion for ≥1 month, without other psychotic symptoms, with preserved functioning apart from the delusion's impact. Subtypes: erotomanic, grandiose, jealous, persecutory, somatic.

— Psychosis occurs only during manic or depressive episodes; mood symptoms predominate.

— Psychosis only during depressive episode; mood-congruent delusions (worthlessness, nihilism, poverty).

— Symptoms develop during or within a month of intoxication/withdrawal; resolve with sobriety. Common: methamphetamine, cocaine, cannabis, LSD, PCP, steroids, levodopa.

— Direct physiologic consequence of medical illness (epilepsy, neurosyphilis, lupus, anti-NMDA encephalitis, brain tumor, Huntington disease).

— DSM-5 folded this into delusional disorder; one person's delusion adopted by a closely associated other.

— Eccentric beliefs, magical thinking, social anxiety — does not reach delusional intensity or psychosis.

Board pearl: The "2-week rule" is the schizoaffective discriminator: psychotic symptoms must persist for ≥2 weeks without mood symptoms at some point in the illness. If psychosis is only present during mood episodes → mood disorder with psychotic features, not schizoaffective.

Schizophrenia:

Schizoaffective disorder:

Delusional disorder:

Bipolar I disorder with psychotic features:

Major depressive disorder with psychotic features:

Substance/medication-induced psychotic disorder:

Psychotic disorder due to another medical condition:

Shared psychotic disorder (folie à deux):

Schizotypal personality disorder:

Key Differentials — Other-Category (Medical, Neurologic, Toxic)

— Acute, fluctuating course, inattention, altered level of consciousness, disorganized thinking, often visual hallucinations. Always rule out before diagnosing primary psychosis.

— Stimulants (cocaine, meth, amphetamine): paranoia, tactile hallucinations ("cocaine bugs"), tachycardia, mydriasis.

— Cannabis (especially high-THC, synthetic cannabinoids): acute psychosis, depersonalization; chronic use raises schizophrenia risk.

— PCP, ketamine: dissociation, nystagmus, violence, analgesia.

— Hallucinogens (LSD, psilocybin): visual hallucinations, synesthesia, intact reality testing usually preserved.

— Alcohol withdrawal: delirium tremens — tremor, tachycardia, hallucinations, seizures.

— Temporal lobe epilepsy — postictal or interictal psychosis.

— Multiple sclerosis, stroke, brain tumor, traumatic brain injury.

— Huntington disease — psychiatric symptoms can precede chorea.

— Lewy body dementia — visual hallucinations, parkinsonism, fluctuating cognition; antipsychotic sensitivity.

— Wilson disease — psychosis + tremor + hepatic dysfunction in young adult.

— Thyrotoxicosis, myxedema, Cushing, Addison, hypoglycemia, hyponatremia, hypercalcemia, hepatic encephalopathy, uremia, B12 deficiency, porphyria.

— Anti-NMDA receptor encephalitis, SLE cerebritis, Hashimoto encephalopathy, neurosarcoidosis.

— Neurosyphilis, HIV, herpes encephalitis, prion disease, cerebral malaria.

— Corticosteroids, anticholinergics, dopamine agonists, isoniazid, interferon, mefloquine, high-dose stimulants.

Step 3 management: First-episode psychosis age >40, abnormal vitals, focal exam findings, visual hallucinations, or rapidly fluctuating consciousness should always trigger MRI brain, full medical workup, and consideration of autoimmune encephalitis before committing to BPD or schizophreniform.

Delirium:

Substance intoxication/withdrawal:

Neurologic disease:

Endocrine/metabolic:

Autoimmune:

Infectious:

Medication-induced:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— BPD: continue antipsychotic for 1–3 months after symptom resolution, then gradual taper over additional 1–3 months with close monitoring for relapse.

— Schizophreniform: continue antipsychotic for at least 12 months after symptom resolution; if symptoms persist past 6 months, diagnosis is reclassified as schizophrenia and indefinite maintenance is typically recommended.

— Consider long-acting injectable (LAI) antipsychotics (paliperidone, aripiprazole monthly, risperidone biweekly) if adherence is a concern, prior nonadherence-related relapse, or patient preference.

— Pill organizers, smartphone reminders, family involvement.

— Coordinated Specialty Care (CSC) for first-episode psychosis (NAVIGATE/RAISE model): team-based with medication management, family psychoeducation, supported employment/education, individualized resilience-focused therapy. Improves long-term outcomes.

— Cognitive behavioral therapy for psychosis (CBTp) for residual symptoms.

— Family psychoeducation: reduces relapse via lowering expressed emotion.

— Supported employment/education (IPS model).

— Assertive Community Treatment (ACT) for high utilizers with recurrent admissions.

— Strongly encourage cannabis cessation — cannabis use doubles relapse risk and worsens functional outcomes.

— Smoking cessation: bupropion or varenicline (no contraindication in stable psychosis), nicotine replacement.

— Annual fasting glucose/HbA1c, lipids, weight/BMI, blood pressure.

— Cardiovascular risk reduction; people with schizophrenia have 15–20 year reduced life expectancy primarily from cardiovascular disease.

Board pearl: A patient leaving the hospital after a first episode of schizophreniform disorder should walk out with: antipsychotic prescription, psychiatry appointment within 7 days, primary care appointment within 30 days, referral to coordinated specialty care, family education materials, crisis line number, and a documented metabolic baseline.

Antipsychotic continuation:

Adherence support:

Psychosocial interventions — evidence-based and Step 3 favored:

Substance use treatment:

Medical comorbidities:

Vaccinations, primary care engagement, dental care.

Follow-Up, Monitoring Parameters, and Rehabilitation

— Within 7 days of psychiatric discharge — strongly evidence-based for reducing readmission and suicide.

— Then every 2–4 weeks during first 3 months while titrating medication.

— Then every 1–3 months once stable.

— Reassess DSM duration criteria at the 1-month and 6-month marks to update diagnosis (BPD → schizophreniform → schizophrenia).

— Positive symptoms (hallucinations, delusions, disorganization).

— Negative symptoms (avolition, alogia, anhedonia, blunted affect) — often emerge later, predict functional outcome.

— Cognitive symptoms (attention, memory, executive function).

— Mood symptoms — depression is common post-psychosis and elevates suicide risk.

— Suicidal ideation at every visit.

— Weight/BMI: baseline, 4 wk, 8 wk, 12 wk, then quarterly.

— Waist circumference, BP: baseline, then annually.

— Fasting glucose/HbA1c, lipid panel: baseline, 12 weeks, then annually (or more often if abnormal).

— AIMS (Abnormal Involuntary Movement Scale) every 6 months to screen for tardive dyskinesia.

— Prolactin if symptomatic (galactorrhea, amenorrhea, sexual dysfunction).

— ECG with QT-prolonging agents.

— Clozapine: weekly CBC × 6 months → biweekly × 6 months → monthly (REMS).

— Supported education/employment, social skills training, peer support, NAMI family-to-family programs.

— Address housing instability, transportation, benefits enrollment (SSI/SSDI if disabling).

— Identify early warning signs (sleep disturbance, social withdrawal, suspiciousness), create written relapse-prevention plan with patient and family.

Step 3 management: The single highest-yield post-discharge intervention is the 7-day follow-up appointment — schedule it before discharge, confirm transportation, and engage family in the appointment when possible.

Follow-up cadence:

Symptom monitoring:

Medication monitoring (APA/ADA consensus):

Rehabilitation and functional recovery:

Trigger and relapse plan:

Ethical, Legal, and Patient Safety Considerations

— Psychosis does not automatically equal incapacity — assess each decision specifically (understanding, appreciation, reasoning, choice — Appelbaum criteria).

— A patient may lack capacity to refuse antipsychotic medication but retain capacity for other medical decisions.

— Document capacity assessment thoroughly; engage psychiatric consultation, ethics committee, or court order for treatment over objection when needed.

— Requires mental illness + dangerousness to self/others or grave disability.

— State-specific holds (e.g., 5150 in California, Baker Act in Florida, "Section 12" in Massachusetts). Know that your state requires due process for longer commitments.

— Patient retains the right to refuse non-emergency medication unless adjudicated incompetent.

— Tarasoff/duty to warn or protect: when a patient makes a specific, credible threat against an identifiable victim, the clinician has a duty to warn the victim, notify law enforcement, and/or hospitalize the patient (state-specific).

— Child abuse, elder abuse, dependent adult abuse: mandatory reporting if suspected, including if patient's psychosis impairs child care.

— HIPAA permits disclosure to family/caregivers for treatment coordination if patient consents or lacks capacity and disclosure is in patient's best interest.

— In emergencies, you may disclose minimum necessary information to ensure safety.

— High-risk window: first 30 days post-discharge — elevated suicide, relapse, and readmission risk. Ensure medication reconciliation, 7-day follow-up, crisis line, and family education.

— Pharmacist medication reconciliation reduces error rates.

— Counsel about driving safety with sedation; some states require physician reporting of impaired drivers.

— Discuss firearm access — restriction during active psychosis is appropriate.

— Encourage psychiatric advance directives during periods of wellness — patient specifies preferred medications, hospitals, and treatment refusals.

Board pearl: A patient with active psychosis tells you he plans to shoot his ex-girlfriend at her workplace tomorrow. Your obligation under Tarasoff is to hospitalize the patient, notify law enforcement, and warn the identified victim — confidentiality does not override imminent specific threats.

Informed consent and capacity:

Involuntary hospitalization:

Mandatory reporting:

Confidentiality:

Transition-of-care safety:

Driving and firearms:

Stigma and advance directives:

High-Yield Associations and Rapid-Fire Clinical Facts

— Brief psychotic disorder: 1 day to <1 month, full return to baseline.

— Schizophreniform: 1 to <6 months.

— Schizophrenia: ≥6 months.

— Schizoaffective: psychosis ≥2 weeks without mood symptoms.

— Delusional disorder: ≥1 month of non-bizarre delusions, no other psychosis.

— Acute onset (symptoms peak within 4 weeks).

— Confusion at the height of psychosis.

— Good premorbid functioning.

— Absence of blunted/flat affect.

— (Mnemonic: "Good prognosis = ACBA".)

— Bereavement, immigration, combat, trauma, postpartum.

Key distinction: BPD ends with full return to baseline functioning — if the patient does not return to baseline, the diagnosis is wrong; reconsider schizophreniform or schizophrenia.

Duration cutoffs (memorize):

Good prognostic features in schizophreniform:

Brief psychotic disorder triggers:

Postpartum psychosis: onset within 4 weeks of delivery, strongly associated with bipolar disorder, recurrence risk 30–50%, infanticide risk 4%, suicide risk 5%.

Cannabis doubles risk of schizophrenia; adolescent-onset use most concerning.

Anti-NMDA receptor encephalitis: young woman + psychosis + dyskinesias + seizures + ovarian teratoma.

First-line acute agitation: olanzapine IM or haloperidol + lorazepam IM.

Highest metabolic burden SGAs: olanzapine > clozapine > quetiapine.

Weight-neutral SGAs: aripiprazole, ziprasidone, lurasidone.

Hyperprolactinemia: risperidone, paliperidone, FGAs.

NMS treatment: dantrolene + bromocriptine + supportive care.

Clozapine: reserved for treatment-resistant schizophrenia (≥2 failed trials); REMS monitoring for agranulocytosis; only antipsychotic shown to reduce suicide risk.

Tardive dyskinesia treatment: valbenazine, deutetrabenazine (VMAT2 inhibitors).

Black-box warning: increased mortality with antipsychotics in elderly dementia patients.

7-day post-discharge follow-up = single highest-yield Step 3 intervention.

Two-thirds of schizophreniform cases progress to schizophrenia or schizoaffective disorder.

Board Question Stem Patterns

Step 3 management: The two pivot points in nearly every stem are (1) duration (anchors the diagnosis) and (2) safety triage (drives the disposition). Identify both within the first read of the vignette.

Stem 1 — Classic BPD with stressor: 26-year-old immigrant develops persecutory delusions 2 weeks after a traumatic relocation; symptoms resolve in 3 weeks with low-dose risperidone, returns to baseline. → Brief psychotic disorder with marked stressor.

Stem 2 — Schizophreniform: 20-year-old college student over 2 months becomes withdrawn, hears voices, accuses roommates of poisoning him; symptoms have persisted for 10 weeks. → Schizophreniform disorder; counsel on likely progression and start SGA.

Stem 3 — Duration crossing 6 months: Schizophreniform patient now at month 7 with persistent symptoms. → Reclassify as schizophrenia; continue antipsychotic indefinitely, intensify psychosocial supports.

Stem 4 — Postpartum psychosis: 28-year-old woman 10 days postpartum with command hallucinations to harm baby. → Immediate admission, supervised contact with infant, antipsychotic + mood stabilizer, evaluate for ECT, screen for bipolar disorder.

Stem 5 — Anti-NMDA encephalitis mimic: 22-year-old woman with new psychosis, orofacial dyskinesias, seizures, autonomic instability. → CSF anti-NMDA receptor antibodies, pelvic imaging for teratoma, IV steroids/IVIG/plasmapheresis, not antipsychotic alone.

Stem 6 — Acute dystonia: Young man develops torticollis 6 hours after IM haloperidol. → IM benztropine 1–2 mg or diphenhydramine 50 mg; switch to SGA going forward.

Stem 7 — NMS: Patient on haloperidol develops 40°C fever, lead-pipe rigidity, CK 12,000, confusion. → Stop antipsychotic, ICU, IV fluids, dantrolene + bromocriptine.

Stem 8 — Substance-induced: 19-year-old after methamphetamine use has paranoia and tactile hallucinations; symptoms resolve over 5 days with sobriety. → Substance-induced psychotic disorder, not BPD.

Stem 9 — Elderly with new psychosis: 72-year-old develops paranoia and visual hallucinations over 2 weeks. → Workup for delirium, dementia (especially Lewy body), stroke, infection before psychiatric diagnosis. Avoid first-generation antipsychotics; if needed, low-dose quetiapine.

Stem 10 — Tarasoff: Patient with psychosis names a specific person he intends to harm. → Hospitalize, warn the identified victim, notify law enforcement.

One-Line Recap

Brief psychotic disorder (<1 month with full return to baseline) and schizophreniform disorder (1–6 months) are duration-defined psychotic syndromes that require ruling out medical, substance, and autoimmune mimics, prompt initiation of a second-generation antipsychotic, robust safety triage, and structured follow-up — with the recognition that roughly two-thirds of schizophreniform cases progress to schizophrenia.

Board pearl: When in doubt on Step 3, anchor on duration first, safety second, workup third, then medication and follow-up — that sequence will carry you through nearly every psychosis vignette on the exam.

Diagnostic stopwatch: BPD <1 month → schizophreniform 1–<6 months → schizophrenia ≥6 months; reassess and reclassify at each duration milestone, and remember that schizoaffective requires ≥2 weeks of psychosis without mood symptoms.

Workup before label: every first-episode psychosis gets CBC, CMP, TSH, B12, RPR, HIV, UDS, β-hCG, ECG, and MRI brain — plus an autoimmune encephalitis screen and pelvic imaging in young women with dyskinesias or seizures.

Treatment essentials: second-generation antipsychotic (aripiprazole, risperidone, olanzapine) with metabolic baseline before initiation; continue 1–3 months past resolution for BPD and ≥12 months for schizophreniform; offer LAI if adherence is a concern; engage coordinated specialty care.

Safety and systems: postpartum psychosis is a never-discharge emergency; Tarasoff applies to specific threats; black-box mortality warning limits antipsychotic use in elderly with dementia; 7-day post-discharge psychiatry follow-up is the single highest-yield prevention intervention.